MicroRNA-30a Mediates Cell Migration and Invasion by Targeting Metadherin in Colorectal Cancer

Abstract

MicroRNAs play critical roles in the occurrence and progression in various cancers including colorectal cancer. Here, we found that microRNA-30a expression was significantly downregulated in colorectal cancer tissues compared to adjacent noncancerous tissues, and the suppression levels of microRNA-30a were significantly associated with tumor differentiation and lymph node metastasis. We also discovered that the expression level of microRNA-30a was inversely proportional to the invasive potential of several colorectal cancer cell lines. Moreover, overexpression of microRNA-30a in colorectal cancer cells inhibited activity of cell migration and invasion. Luciferase reporter assay confirmed metadherin could be a direct target of microRNA-30a, as the overexpression of microRNA-30a decreased metadherin expression at both the protein and messenger RNA levels. Furthermore, the knockdown of metadherin expression in SW620 significantly decreased cell metastasis and invasion. The upregulation of metadherin at the protein level negatively correlated with the expression of microRNA-30a in colorectal cancer tissues, and this upregulation could partially attenuate the effect induced by microRNA-30a. These findings indicate that microRNA-30a may act as a tumor suppressor in colorectal cancer and that microRNA-30a represses cell migration and invasion by decreasing metadherin, highlighting the therapeutic potential of microRNA-30a and metadherin in colorectal cancer treatment.

A specific microRNA profile as predictive biomarker for systemic treatment in patients with metastatic colorectal cancer

“…39,40 Although, for miR-17, miR-20a, miR-30a, and miR-92a previous studies have shown no significant relation between miRNA expression and stage. 20,41,42 miR-92b expression has not been related to stage before and Zhu et al found lower levels of miR-98 expression in patients with stage III-IV disease compared to patients with stage I-II disease. 43 Since there was no significant difference in miRNA expression between patients with stage I-III (32%) vs stage IV (66.7%) disease in the previous cohort (see Table 1), we considered it worthwhile testing this signature in a cohort consisting of only patients with stage IV disease, who are starting first-line palliative systemic therapy.…”

Expression of Circulating miR-155, miR-21, miR-221, miR-30a, miR-34a and miR-29a: Comparison of Colonic and Rectal Cancer

“…Our results showed that the expression of miR-30a was slightly, but statistically significantly higher in the blood of patients with colonic or rectal cancer and in stage II and III compared to controls. This is contradictory to the literature since many publications mention that miR-30a has an antimetastatic effect and expression was lower in patients with colorectal tumours (14)(15)(16)(17).…”

Clinical Diagnostic Value for Colorectal cancer Based on Serum CEA, CA24-2 and CA19-9

“…These biomarkers can be used for early diagnosis, individualized treatment and prognosis of colorectal cancer [36]. For example, hsa-mir-183-5p and hsa-mir-21-5p [37], hsa-mir-30a [38], hsa-mir-96 [39], hsa-mir-21 [40] for diagnosis of colorectal cancer. And hsa-mir-143 and hsa-mir-145 for prognosis of colorectal cancer [41].…”